Overview

Dociparstat (DSTAT) in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia (AML) (DASH AML)

Status:
Recruiting

Trial end date:
2026-02-15

Target enrollment:

Participant gender:

Summary

Phase 3 study to evaluate the efficacy and safety of dociparstat sodium in adults with newly diagnosed untreated AML with adverse or intermediate genetic risk.

Phase:

Phase 3

Details

Lead Sponsor:

Chimerix

Treatments:

Heparin